ExaNK

N/A

Report date: 2025/03/20 15:54:16

Base Information

Drug NameExaNK
Drug Alias Nameallogeneic iPSC-derived NK cell therapy (Exacis Biotherapeutics/Factor Bioscience)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cells stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExacis Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesExacis Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A